Edgemont Capital Completes Sale Of Vince & Associates Clinical Research
Edgemont enhances its position as the leading M&A advisor to clinical research site companies
Transaction highlights growing demand from large pharma, biotech companies for early development clinical trials in patient populations
NEW YORK, May 15, 2013 /PRNewswire/ — Edgemont Capital Partners (“Edgemont”), a specialty investment bank focused on the merger and acquisition advisory needs of healthcare companies, has acted as exclusive financial advisor to Vince and Associates Clinical Research (“Vince and Associates”) in its sale to Altasciences Group. Vince and Associates manages complex early development clinical drug trials at its state-of-the-art research facility in Overland Park, Kansas. The transaction highlights growing demand from large pharmaceutical and biotechnology companies for conducting early development studies in patient populations. Terms of the deal were not announced.
This is the ninth transaction completed by Edgemont on behalf of clinical research site services companies and one of the largest to date, further establishing Edgemont as the leading healthcare M&A advisor to clinical research site companies. Prior transactions completed by Edgemont include the sale of Miami Research Associates, Inc. to QPS, LLC, the sale of California Clinical Trials, Inc. to Parexel Inc., and the sale of Lifetree Clinical Research, LLC to CRI Worldwide, LLC, among others.
Vince and Associates is a leader in the successful recruitment and retention of special patient populations in complex early development clinical drug trials. The company’s approach utilizes study teams led by highly experienced principal investors who are intimately involved in all aspects of the clinical trial process. The transaction with Altasciences is a further reflection of the significant industry demand for specialized outsourcing services on the part of large pharmaceutical and biotechnology companies.
We are seeing strong acquisition interest in sophisticated site services companies like Vince and Associates that have unique and established access to highly desirable patient populations and a proven track record of research excellence,” said David K. Blume, co-founder and Managing Director at Edgemont. “Access to these populations is critical to the drug development success of pharmaceutical and biotechnology companies, and represents tremendous value.”
Altasciences is owned by Kilmer Capital Partners, which also owns AlgorithmePharma, a Montreal based full service early stage clinical CRO. Both Vince and Associates Clinical Research and AlgorithmePharma operate with a common mission to provide the highest quality early stage clinical development services to an international customer base of pharmaceutical, biotechnology and generic companies with a focus on customer service.
About Edgemont Capital Partners
Edgemont Capital Partners, L.P. (www.edgemontcapital.com) is a specialty investment bank focused on the advisory needs of healthcare companies worldwide. The firm’s deep healthcare industry knowledge, extensive relationship network and substantial transaction expertise allows Edgemont to address healthcare companies’ strategic advisory (M&A) and financing needs with great success. Edgemont Capital Partners, L.P. provides mergers and acquisition advisory, restructuring advisory, board advisory, valuation and private placements services. Investment banking services are provided by Edgemont Capital Partners, L.P., a registered broker-dealer and member of FINRA and SIPC.
About Vince & Associates Clinical Research
Vince & Associates Clinical Research has provided clinical research services to the biopharmaceutical industry for more than a decade. Proud to be recognized in the industry as a “Center of Research Excellence”, Vince & Associates has become a premier clinical research site by utilizing The Physician Research Model(R) of operation where study teams are led by highly experienced principal investigators intimately involved in all aspects of the clinical trial process.
Vince & Associates recently opened a state-of-the-art, multimillion-dollar, 90-bed clinical pharmacology unit that combines the ultimate in subject safety and luxury. This new unit has the upscale atmosphere necessary for the recruitment and retention of study volunteers in both short- and long-term clinical trials, from the safety and security of the controlled access unit to the added features of a movie theater and game rooms.
Chris Sullivan, MacMillan Communications, 212.473.4442, email@example.com